ADMA Biologics, Inc.
ADMA Biologics, Inc. (Nasdaq: ADMA) is a U.S. biopharmaceutical company that develops, manufactures and markets plasma-derived biologics for people with immune deficiencies or at risk of certain infectious diseases. Its marketed products include ASCENIV and BIVIGAM, intravenous immune globulins for primary… From the company’s description.
Over the twelve months to Sep 30, 2026, ADMA Biologics, Inc. reported revenue of $519.15M, up 6.3% from a year earlier, and net income of $182.41M. Its operating margin was 46.5%, and operations generated $140.79M in cash. In fiscal 2025, it reported revenue of $510.17M, up 19.6% from fiscal 2024, and net income of $146.93M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ADMA Biologics, Inc. does
In the company’s own words
ADMA Biologics, Inc. (Nasdaq: ADMA) is a U.S. biopharmaceutical company that develops, manufactures and markets plasma-derived biologics for people with immune deficiencies or at risk of certain infectious diseases. Its marketed products include ASCENIV and BIVIGAM, intravenous immune globulins for primary immunodeficiency, and Nabi-HB, a hepatitis B immune globulin for specified exposure settings. Products are used by physician specialists and supplied to treatment sites including hospitals, infusion centers, physician offices and home healthcare providers. ADMA reports two business segments: ADMA BioManufacturing, which produces and sells its therapies and provides certain contract manufacturing and laboratory services, and Plasma Collection Centers, which collects plasma for internal manufacturing and sells surplus plasma to third parties. Its Boca Raton facility has peak annual processing capability of up to 600,000 liters. The company operated ten U.S. plasma collection centers at December 31, 2025, and has agreed to divest three, after which it expects to operate seven. Its pipeline includes SG-001, a potential pneumococcal hyperimmune globulin.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- RAMSEY, NJ
- Fiscal year end
- December
- CIK
- 1368514
- SIC
- 2836
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ADMA Biologics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in ADMA Biologics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · ADMA Biologics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ADMA Biologics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ADMA Biologics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ADMA Biologics, Inc.'s last four quarterly filings that the numbers alone won't show?”